Literature DB >> 12142090

Radiotherapy alone in patients with advanced nasopharyngeal cancer: comparison with an intergroup study. Is combined modality treatment really necessary?

Edward Chow1, David Payne, Brian O'Sullivan, Melania Pintilie, Fei Fei Liu, John Waldron, Padraig Warde, Bernard Cummings.   

Abstract

PURPOSE: To examine the outcome of radiotherapy (RT) alone in patients with advanced nasopharyngeal cancer (NPC) and to compare the results with those reported by the Intergroup study 0099 (IGS) comparing RT to combined modality therapy (CMT).
MATERIALS AND METHODS: During the period 1985-1992, 198 NPC patients presenting without distant metastatic disease were treated for cure. Of these, 172 had stage III/IV (UICC 1987, 1992). Planned RT was 2 Gy/day fraction to 60-66 Gy to the primary tumor, with 50 and 60 Gy to the node negative and to palpable nodes, respectively. Outcomes included overall survival (OS) and disease-free survival (DFS), defined from the time of registration at our institution.
RESULTS: The TNM categories and other prognostic factors were similar to the IGS, though 80% had stage IV compared to 91% in IGS. The 5 year OS and DFS for the 172 patients with stage III/IV disease were 62 and 48%, respectively, as compared to the IGS results of OS 37% and DFS 29% for RT alone, and OS 67% and DFS 58% for the CMT arm of IGS. When the distribution of adverse prognostic factors was balanced between both studies the comparative results were unchanged.
CONCLUSIONS: The early results for RT alone of this single institution experience are superior to those of the IGS control arm (RT), while somewhat inferior to those reported in the chemo-radiotherapy arm. The surprisingly poor outcome of the IGS/RT control arm may have resulted by chance, suggesting the need for a confirmatory randomized trial to fully establish the role of combined chemotherapy and radiation, as used in the IGS. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12142090     DOI: 10.1016/s0167-8140(02)00132-9

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

1.  Inhibiting ERp29 expression enhances radiosensitivity in human nasopharyngeal carcinoma cell lines.

Authors:  Lin Qi; Ping Wu; Xin Zhang; Yuanzheng Qiu; Weihong Jiang; Donghai Huang; Yong Liu; Pingqing Tan; Yongquan Tian
Journal:  Med Oncol       Date:  2011-04-11       Impact factor: 3.064

2.  Alternative endpoints to the 5-year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients.

Authors:  Chen Chen; Wei Yi; Jin Gao; Xiao-Hui Li; Lu-Jun Shen; Bo-Fei Li; Zi-Wei Tu; Ya-Lan Tao; Chang-Bin Jiang; Yun-Fei Xia
Journal:  Mol Clin Oncol       Date:  2014-02-20

3.  Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy.

Authors:  Ping Wu; Hua Zhang; Lin Qi; Qingping Tang; Yaoyun Tang; Zhihai Xie; Yunxia Lv; Suping Zhao; Weihong Jiang
Journal:  Oncol Rep       Date:  2011-12-08       Impact factor: 3.906

4.  Prognostic model for survival of local recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy.

Authors:  Y-M Tian; Y-H Tian; L Zeng; S Liu; Y Guan; T-X Lu; F Han
Journal:  Br J Cancer       Date:  2013-12-12       Impact factor: 7.640

5.  The feasibility of omitting irradiation to the contralateral lower neck in stage N1 nasopharyngeal carcinoma patients.

Authors:  Weixu Hu; Guopei Zhu; Xiyin Guan; Xiaoshen Wang; Chaosu Hu
Journal:  Radiat Oncol       Date:  2013-10-04       Impact factor: 3.481

Review 6.  Six fractions weekly as accelerated fraction radiotherapy: Is it applicable for nasopharyngeal cancer? A review.

Authors:  Arundito Widikusumo; Schandra Purnamawati
Journal:  Contemp Oncol (Pozn)       Date:  2019-10-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.